SEC Company Response from Vaxart, Inc. (VXRT) (CIK 0000072444) (VXRT) — Oct 16, 2013
Vaxart, Inc. (VXRT) (CIK 0000072444)
Date: Oct. 16, 2013 · CIK: 0000072444 · Accession: 0001437749-13-013084
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-190594
Letter
bota20131016_corresp.htm
October 16, 2013
Via EDGAR
Securities and Exchange Commission
Division of Corporation Finance
100 F Street, NE
Washington, DC 20549-4561
Attn: Mr. Jeffrey P. Riedler, Assistant Director
Re: Biota Pharmaceuticals, Inc.
Registration Statement on Form S-3
File No. 333-190594
Ladies and Gentlemen:
Pursuant to Rule 461 of the Securities Act of 1933, as amended, Biota Pharmaceuticals, Inc. (the “Company”) hereby requests that the Securities and Exchange Commission (the “Commission”) accelerate the effectiveness of the above-referenced Registration Statement to 4:00 p.m., Eastern Standard Time, on Thursday, October 17, 2013, or as soon thereafter as practicable.
The Company acknowledges that:
●
should the Commission or the staff, acting pursuant to delegated authority, declare the filing effective, such declaration does not foreclose the Commission from taking any action with respect to the filing;
●
the action of the Commission or the staff, acting pursuant to delegated authority, in declaring the filing effective, does not relieve the Company from its full responsibility for the adequacy and accuracy of the disclosure in the filing; and
●
the Company may not assert staff comments and the declaration of effectiveness as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States.
Please contact Michael S. Kagnoff of DLA Piper LLP (US) with any questions or comments at (858) 638-6722. Thank you for your assistance with this filing.
Very truly yours,
Biota Pharmaceuticals, Inc.
Show Raw Text
CORRESP 1 filename1.htm bota20131016_corresp.htm October 16, 2013 Via EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, NE Washington, DC 20549-4561 Attn: Mr. Jeffrey P. Riedler, Assistant Director Re: Biota Pharmaceuticals, Inc. Registration Statement on Form S-3 File No. 333-190594 Ladies and Gentlemen: Pursuant to Rule 461 of the Securities Act of 1933, as amended, Biota Pharmaceuticals, Inc. (the “Company”) hereby requests that the Securities and Exchange Commission (the “Commission”) accelerate the effectiveness of the above-referenced Registration Statement to 4:00 p.m., Eastern Standard Time, on Thursday, October 17, 2013, or as soon thereafter as practicable. The Company acknowledges that: ● should the Commission or the staff, acting pursuant to delegated authority, declare the filing effective, such declaration does not foreclose the Commission from taking any action with respect to the filing; ● the action of the Commission or the staff, acting pursuant to delegated authority, in declaring the filing effective, does not relieve the Company from its full responsibility for the adequacy and accuracy of the disclosure in the filing; and ● the Company may not assert staff comments and the declaration of effectiveness as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States. Please contact Michael S. Kagnoff of DLA Piper LLP (US) with any questions or comments at (858) 638-6722. Thank you for your assistance with this filing. Very truly yours, Biota Pharmaceuticals, Inc. By: /s/ Russell H. Plumb Name: Russell H. Plumb Title: President and Chief Executive Officer